News | January 16, 2007

Senate Bill Aims to Stop Generic Drug Pacts

Jan. 17, 2007 - The chairman of the Senate Judiciary Committee said on Wednesday he will introduce legislation to prevent drugmakers from striking deals that restrict the introduction of cheaper generic drugs.

The bill planned by Sen. Patrick Leahy, a Vermont Democrat, targets an increasingly common tactic used by brand-name drug makers — legal settlements that involve payments to generic rivals to restrict the sale of generic alternatives.

Leahy said the bill is supported by several other senators, including Republican Charles Grassley of Iowa.

"Congress never intended brand-name drug companies to be able to pay off generic companies not to produce generic medicines," Leahy said at a Judiciary Committee hearing. "That would be a shame, harmful to consumers and a crime."

During the hearing, a government antitrust official warned that legal settlements between major drugmakers and their generic rivals were a fast-growing problem that is stunting competition in the market for prescription drugs.

Generic drugs are typically cheaper for consumers to buy than brand name drugs, and the Federal Trade Commission has filed several lawsuits in recent years challenging the settlements as anti-competitive.

In some cases, the FTC contended the settlements are a way for drugmakers to pay generics to stay out of the market.

The industry has been emboldened to forge such agreements by recent court rulings that have derailed several of the FTC's legal challenges.

In one key decision in 2005, an appeals court in Atlanta overturned an FTC ruling that said Schering-Plough Corp. had illegally kept cheaper versions of its blood pressure drug K-Dur off the market through patent settlements with generic competitors. The U.S. Supreme Court turned down a petition to review the case last year.

Under federal law, drugmakers are allowed to seek FDA approval for generic versions of brand-name drugs before a drug's patent expires. They must certify that the patent is invalid or will not be infringed by the new generic version.

Related Content

Guerbet Showcases Ongoing Collaboration With IBM Watson at RSNA 2018
News | Clinical Decision Support | November 21, 2018
Guerbet LLC USA will feature its digital solutions including its ongoing collaboration with IBM Watson Health in...
Clarius Mobile Health Announces Clarius AI Collective Intelligence Ultrasound Platform
News | Ultrasound Imaging | November 21, 2018
Clarius Mobile Health will announce a new collective intelligence ultrasound platform at this year's Radiological...
Philips Launches IntelliSpace Discovery Research Platform at RSNA
Technology | Artificial Intelligence | November 20, 2018
Ahead of the 2018 Radiological Society of North America Annual Meeting (RSNA), Nov. 25-30 in Chicago, Royal Philips...
QView Medical Showcases QVCAD for ABUS Exams at RSNA 2018
News | Ultrasound Women's Health | November 19, 2018
QView Medical will showcase QVCAD, the first U.S. Food and Drug Administration (FDA)-approved artificial intelligence (...
Technology | Archive Cloud Storage | November 19, 2018
November 19, 2018 — Intelerad Medical Systems announced the launch of the nuage Disaster Recovery (DR) Platform.
Sponsored Content | Case Study | Enterprise Imaging | November 16, 2018
Centricity Clinical Archive Analytics uses Microsoft Azure and Power BI Embedded to derive intelligence from the data
Lunit Unveiling AI-Based Mammography Solution at RSNA 2018
News | Mammography | November 15, 2018
Medical artificial intelligence (AI) software company Lunit will be returning to the 104th Radiological Society of...
Life Image and Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and announced a new strategic partnership that will facilitate the adoption and enhancement of...
News | Enterprise Imaging | November 14, 2018
Konica Minolta Healthcare Americas Inc. will showcase new features and tools for the Exa Enterprise Imaging platform at...